Annals of Clinical Microbiology and Antimicrobials

Table 4 Antimicrobial susceptibility for ESBL-positive Escherichia coli and Klebsiella pneumoniae

From: Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

		ESBL-producingE. coli	ESBL-producingK. pneumoniae
		N = 277	N = 584
Amikacin	MIC ₅₀	4	16
	MIC ₉₀	16	32
	%S	94.9	77.1
Amoxi-clav	MIC ₅₀	16	16
	MIC ₉₀	≥64	≥64
	%S	29.6	29.1
Ampicillin	MIC ₅₀	≥64	≥64
	MIC ₉₀	≥64	≥64
	%S	0.7	0.0
Carbapenems	MIC ₅₀	≤0.06	0.12
	MIC ₉₀	0.25	16
	%S	98.2	74.0
Cefepime	MIC ₅₀	32	16
	MIC ₉₀	≥64	≥64
	%S	34.3	48.1
Ceftriaxone	MIC ₅₀	≥128	64
	MIC ₉₀	≥128	≥128
	%S	2.2	3.1
Levofloxacin	MIC ₅₀	≥16	≥16
	MIC ₉₀	≥16	≥16
	%S	5.8	19.9
Minocycline	MIC ₅₀	4	4
	MIC ₉₀	≥32	≥32
	%S	61.0	54.8
Pip-taz	MIC ₅₀	4	128
	MIC ₉₀	128	≥256
	%S	79.4	40.1
Tigecycline	MIC ₅₀	0.25	1
	MIC ₉₀	0.5	2
	%S	100	92.1

% S, % susceptible, amoxi-clav amoxicillin-clavulanate, pip-taz piperacillin-tazobactam, carbapenems = imipenem/meropenem.

Back to article page

ISSN: 1476-0711

Contact us

Submission enquiries: journalsubmissions@springernature.com